Massachusetts Society of Clinical Oncologists - AstraZeneca announced that the FDA has approved a new indication for LYNPARZA® (olaparib)

"The Voice of Oncology in Massachusetts"

AstraZeneca announced that the FDA has approved a new indication for LYNPARZA® (olaparib)

March 14, 2022 8:46 AM | Katy Monaco (Administrator)

AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. Please see the attached document for more information regarding the use of LYNPARZA in this new indication. Press Release.

ADDRESS

860 Winter Street, Waltham, MA, 02451

tel: 781.434.7329

msco@mms.org

Home
About
Advocacy
Membership
Events
Resources

Join Our Mailing List